BUILDING SAFER AND MORE POTENT TREATMENTS
OUR SOLUTION
Deliver safer and more potent ADCs Targeting Surface Protein Complexes
DISCOVERY
As reported by Centrose in Nature Communications, a cell’s Surfaceome is a collection of distinct interacting proteins that allow the cell to function and communicate with other cell types. Importantly, these networks are cell type specific and thus can be targeted with precision medicines.
EDCs are True Next-Gen ADCs
EDCs are antibody drug conjugates (ADCs) that don’t require internalization, nor do they require breakdown. In fact, for EDCs to work, the drug has to be attached to the antibody and the two target proteins have to be outside of the cell. This is why we named them Extracellular Drug Conjugates or EDCs, a true Next-Gen ADC platform.
Background of Extracellular Targeting
Centrose discovered that a druggable protein called the sodium-potassium pump interacts with multiple proteins on the outer surface of diseased cells. Now termed the “surfaceome”, scientists around the world are currently working to determine the roles and makeup of these plasma membrane interactions. In an effort to create new medicines, Centrose decided to exploit the existence of the surfaceome and develop a new type of ADC that selectively targets these communities in a disease specific manner. We call these new ADCs, Extracellular Drug Conjugates (EDCs) because both the antibody and drug targets interact which each other on the extracellular side of plasma membrane.
Since our initial discovery, Centrose has developed multiple EDCs that display high potency and selectivity. These EDCs were also found to be safe when tested at efficacious levels in non-human primate models. Also, many of the EDCs developed use antibodies that could not be used for making ADCs, a fact that should expand the scope of the antibody drug conjugate field.
As we reported in cell press publication, Centrose found that antibody targets like CD20, dysadherin and CD38 are involved in cancer cell surface communities in a cell specific manner. With this knowledge, Centrose has since developed a number of EDCs for different cancer types like lung, pancreatic and lymphomas.
PIPELINE
EDC9 targets drug resistant NHL.
EDC1 targets metastatic cancers.
EDC8 targets certain types of lymphoma.
